[go: up one dir, main page]

DK469886A - Farmaceutisk praeparat af en type, som undergaar vaeske-gel-fase overgang - Google Patents

Farmaceutisk praeparat af en type, som undergaar vaeske-gel-fase overgang Download PDF

Info

Publication number
DK469886A
DK469886A DK469886A DK469886A DK469886A DK 469886 A DK469886 A DK 469886A DK 469886 A DK469886 A DK 469886A DK 469886 A DK469886 A DK 469886A DK 469886 A DK469886 A DK 469886A
Authority
DK
Denmark
Prior art keywords
type
phase transition
gel phase
understands
fluid
Prior art date
Application number
DK469886A
Other languages
English (en)
Other versions
DK469886D0 (da
DK170500B1 (da
Inventor
Claude Mazuel
Marie-Claire Friteyre
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of DK469886D0 publication Critical patent/DK469886D0/da
Publication of DK469886A publication Critical patent/DK469886A/da
Application granted granted Critical
Publication of DK170500B1 publication Critical patent/DK170500B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK469886A 1985-10-03 1986-10-02 Farmaceutisk præparat, der undergår væske-gel faseovergang DK170500B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8514689A FR2588189B1 (fr) 1985-10-03 1985-10-03 Composition pharmaceutique de type a transition de phase liquide-gel
FR8514689 1985-10-03

Publications (3)

Publication Number Publication Date
DK469886D0 DK469886D0 (da) 1986-10-02
DK469886A true DK469886A (da) 1987-04-04
DK170500B1 DK170500B1 (da) 1995-10-02

Family

ID=9323509

Family Applications (1)

Application Number Title Priority Date Filing Date
DK469886A DK170500B1 (da) 1985-10-03 1986-10-02 Farmaceutisk præparat, der undergår væske-gel faseovergang

Country Status (25)

Country Link
US (1) US4861760A (da)
EP (1) EP0227494B1 (da)
JP (1) JPH0667853B2 (da)
KR (1) KR940000229B1 (da)
CN (1) CN1046094C (da)
AT (1) ATE72990T1 (da)
AU (1) AU595240B2 (da)
CA (1) CA1280367C (da)
CY (1) CY1779A (da)
DE (2) DE227494T1 (da)
DK (1) DK170500B1 (da)
ES (1) ES2002401A6 (da)
FI (1) FI91217C (da)
FR (1) FR2588189B1 (da)
GR (1) GR862444B (da)
HK (1) HK42594A (da)
IE (1) IE59464B1 (da)
IL (1) IL80156A (da)
LU (1) LU88694I2 (da)
LV (1) LV5725B4 (da)
NL (1) NL950012I1 (da)
NO (2) NO173212C (da)
NZ (1) NZ217662A (da)
PT (1) PT83471B (da)
ZA (1) ZA867464B (da)

Families Citing this family (372)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095026A (en) * 1983-02-04 1992-03-10 University Of Iowa Research Foundation Prodrugs of carbonic anhydrase inhibitors
US5200180A (en) * 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
FR2618333B1 (fr) * 1987-07-20 1990-07-13 Merck Sharp & Dohme Composition pharmaceutique et/ou cosmetique a usage topique contenant de la gomme rhamsam
US5843156A (en) 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5034406A (en) * 1989-09-26 1991-07-23 Allergan, Inc. Method for reducing or maintaining intraocular pressure
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
FR2653018A1 (fr) 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique non solide a base de microparticules de polymere contenant au moins un principe actif en suspension dans un milieu dispersant et procede de preparation de ladite composition.
FR2653021A1 (fr) * 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
US5141928B1 (en) * 1989-12-20 1995-11-14 Brujo Inc Ophthalmic medication
US5496471A (en) * 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
FR2657018A1 (fr) * 1990-01-12 1991-07-19 Merck Sharp & Dohme Composition ophtalmique fluide a base de microparticules lipidiques contenant au moins un principe actif et son procede de preparation.
US5593683A (en) * 1990-05-01 1997-01-14 Mdv Technologies, Inc. Method of making thermoreversible polyoxyalkylene gels
US5298260A (en) * 1990-05-01 1994-03-29 Mediventures, Inc. Topical drug delivery with polyoxyalkylene polymer thermoreversible gels adjustable for pH and osmolality
US5252318A (en) * 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
CA2044878C (en) * 1990-08-07 2000-12-26 Tacey X. Viegas Thermally reversible and irreversible gels
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5847023A (en) * 1990-10-26 1998-12-08 Mdv Technologies, Inc. Thermal irreversible gel corneal contact lens formed in situ
JP2594486B2 (ja) * 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) * 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
SG84487A1 (en) 1991-04-17 2001-11-20 Merck & Co Inc Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a b-adrenergic antagonist
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
HU220864B1 (en) * 1993-04-16 2002-06-29 Wakamoto Pharma Co Ltd Reversible, thermally gelling water-base medicinal compositions
SE9301877D0 (sv) * 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
US5545617A (en) * 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
IL114193A (en) * 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5585398A (en) * 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5827835A (en) * 1994-08-30 1998-10-27 Alcon Laboratories, Inc. Thermally-gelling emulsions
JPH09508143A (ja) * 1994-08-30 1997-08-19 アルコン ラボラトリーズ，インコーポレイテッド セルロースエーテルを含む熱ゲル化薬剤送達ビヒクル
US5516808A (en) * 1994-10-27 1996-05-14 Sawaya; Assad S. Topical cellulose pharmaceutical formulation
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6165490A (en) * 1996-04-05 2000-12-26 Staar Surgical Ag Biological material, method of preparing such materials, uses thereof and products made therefrom
US6172054B1 (en) 1995-06-15 2001-01-09 Alcon Laboratories, Inc. Combination therapy for lowering and controlling intraocular pressure
US5843470A (en) * 1995-10-06 1998-12-01 Mdv Technologies, Inc. Method and composition for inhibiting post-surgical adhesions
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
WO1997018812A1 (en) * 1995-11-17 1997-05-29 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
US5866120A (en) * 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US5641532A (en) * 1995-12-15 1997-06-24 The Procter & Gamble Company Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems by including gellan gum
AU1671997A (en) 1996-02-13 1997-09-02 Dainippon Pharmaceutical Co. Ltd. Drug delivery system using galactoxyloglucan
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
KR20010006027A (ko) * 1997-04-03 2001-01-15 포인트 바이오메디칼 코퍼레이션 방광내 약물 송달 시스템
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
ATE225392T1 (de) 1997-07-29 2002-10-15 Alcon Lab Inc Konditionierungslösungen für die pflege von harten kontaktlinsen
AU8570498A (en) * 1997-07-29 1999-02-22 Alcon Laboratories, Inc. Switchable viscoelastic systems containing galactomannan polymers and borate
ES2302881T3 (es) 1997-07-29 2008-08-01 Alcon Laboratories, Inc. Composiciones oftalmicas que contienen polimeros de galactomanana y borato.
US20040063678A1 (en) * 1997-10-06 2004-04-01 Bausch & Lomb Incorporated Dexamethasone Gel
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6312667B1 (en) * 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of etching hard tissue in the oral environment
US6669927B2 (en) 1998-11-12 2003-12-30 3M Innovative Properties Company Dental compositions
US6312666B1 (en) * 1998-11-12 2001-11-06 3M Innovative Properties Company Methods of whitening teeth
EA004050B1 (ru) * 1998-12-11 2003-12-25 Бакулиш Мафатлал Хамар Способ изготовления состава местных бета-блокаторов улучшенного действия
US20030032634A1 (en) * 2001-06-01 2003-02-13 Piganelli Jon D. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
US6544975B1 (en) 1999-01-25 2003-04-08 National Jewish Medical And Research Center Substituted porphyrins
WO2001032181A2 (en) 1999-11-01 2001-05-10 Alcon Universal Ltd. Pharmaceutical compositions containing a fluoroquinolone antibiotic drug and xanthan gum
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
PL199321B1 (pl) 2000-07-28 2008-09-30 Alcon Inc Kompozycje farmaceutyczne zawierające tobramycynę i gumę ksantanową
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
JP2002154989A (ja) * 2000-11-14 2002-05-28 Lion Corp 眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
US7084130B2 (en) * 2001-12-11 2006-08-01 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
CA2431368C (en) * 2000-12-20 2006-08-08 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
US20090258955A1 (en) * 2000-12-20 2009-10-15 Alcon, Inc. Intraocular irrigating solution having improved flow characteristics
AU2002230504A1 (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic irrigating solution adapted for use in lasik surgery
WO2002049611A2 (en) * 2000-12-20 2002-06-27 Alcon, Inc. Ophthalmic lubricating solution adapted for use in lasik surgery
AU2002228955B2 (en) * 2000-12-20 2005-09-29 Alcon Inc. Solution for removing cataracts via liquefracture
US20040121947A1 (en) * 2000-12-28 2004-06-24 Oklahoma Medical Research Foundation Compounds which inhibit beta-secretase activity and methods of use thereof
US20020172712A1 (en) * 2001-03-19 2002-11-21 Alan Drizen Antiemetic, anti-motion sustained release drug delivery system
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
DE60228294D1 (en) * 2001-06-05 2008-09-25 Ronald Aung-Din Topische migränetherapie
US20080199524A1 (en) * 2001-08-10 2008-08-21 Toray Industries, Inc. Eyedrops containing particulate agar
KR20040023740A (ko) 2001-08-10 2004-03-18 도레이 가부시끼가이샤 다당류 함유 조성물 및 그의 용도
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
JP4547152B2 (ja) * 2001-10-23 2010-09-22 オクラホマ メディカル リサーチ ファウンデーション β−セクレターゼ阻害剤および使用方法
US20060234944A1 (en) * 2001-10-23 2006-10-19 Oklahoma Medical Reseach Foundation Beta-secretase inhibitors and methods of use
US6620405B2 (en) 2001-11-01 2003-09-16 3M Innovative Properties Company Delivery of hydrogel compositions as a fine mist
MXPA04008171A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7642258B2 (en) * 2002-04-19 2010-01-05 Allergan, Inc. Combination of brimonidine and timolol for topical ophthalmic use
US7030149B2 (en) 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
AU2003241398A1 (en) * 2002-05-06 2003-11-17 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
CA2511217A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
WO2004112723A2 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
KR20060121151A (ko) * 2003-11-10 2006-11-28 도레이 가부시끼가이샤 다당류 함유 조성물 및 누액층 안정화 점안제
WO2005060933A1 (en) * 2003-12-11 2005-07-07 Alcon, Inc. Ophthalmic compositions containing a polysaccharide/borate gelling system
US20050129770A1 (en) * 2003-12-11 2005-06-16 Alcon, Inc. Ophthalmic compositions containing a PVA/borate gelling system
JP4771044B2 (ja) * 2004-09-15 2011-09-14 大正製薬株式会社 粘膜適用液剤
JP2008513497A (ja) * 2004-09-17 2008-05-01 コメンティス，インコーポレーテッド メマプシン２βセクレターゼ活性を阻害するアミノ含有化合物およびその使用方法
US20080207527A1 (en) * 2004-09-17 2008-08-28 Comentis, Inc. Bicyclic Compounds Which Inhibit Beta-Secretase Activity and Methods of Use Thereof
CN101035537A (zh) * 2004-10-01 2007-09-12 默克公司 治疗眼部疾病的组合物和方法
EP1831225A2 (en) 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
US20070059274A1 (en) * 2004-12-01 2007-03-15 Bahram Asgharian Ophthalmic compositions containing a PVA/borate gelling system
WO2006083927A2 (en) * 2005-01-31 2006-08-10 Coram Bioscience, Inc. Antimicrobial agent
NZ562314A (en) * 2005-04-08 2010-02-26 Comentis Inc Compounds which inhibit beta-secretase activity and methods of use thereof
JP2009501725A (ja) * 2005-07-15 2009-01-22 チャクシュ・リサーチ・インコーポレーテッド 糖尿病の眼科合併症の予防及び治療
US7534795B2 (en) * 2005-10-25 2009-05-19 Allergan, Inc. Compounds and their use related to compositions for treating disease
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
TW200808375A (en) 2006-05-12 2008-02-16 Otsuka Pharma Co Ltd Hydrogel suspension and manufacturing process thereof
KR100802534B1 (ko) 2006-06-13 2008-02-14 주식회사태준제약 저자극성 점안제 조성물 및 이의 제조 방법
CN101541783B (zh) 2006-06-30 2014-10-01 苏尼西斯制药有限公司 吡啶酮基pdk1抑制剂
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US20100286145A1 (en) * 2007-07-26 2010-11-11 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
US8299267B2 (en) * 2007-09-24 2012-10-30 Comentis, Inc. (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating
KR20100133980A (ko) * 2008-03-07 2010-12-22 썬 파마 어드밴스트 리서치 컴패니 리미티드 안약 조성물
WO2010016965A2 (en) 2008-05-23 2010-02-11 National Jewish Health Methods for treating injury associated with exposure to an alkylating species
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
US8618096B2 (en) * 2008-07-21 2013-12-31 The Regents Of The University Of California Prodrug compositions and methods for using the same in treating cancer and malaria
CA2737388C (en) 2008-09-15 2017-07-11 Peter Walter Methods and compositions for modulating ire1, src, and abl activity
JP2010132587A (ja) * 2008-12-03 2010-06-17 Teika Seiyaku Kk 眼科用剤
US8580947B2 (en) 2009-02-05 2013-11-12 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US8470997B2 (en) * 2009-02-05 2013-06-25 Gene Signal International Sa Pharmaceutical composition for preventing, stabilising and/or inhibiting blood and lymph vascularization
US20100216877A1 (en) * 2009-02-20 2010-08-26 Micro Labs Limited Storage Stable Prostaglandin Product
BR112012003637A2 (pt) 2009-08-17 2017-04-25 Memorial Sloan Kettering Cancer Center "compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos"
EP2473049B1 (en) 2009-09-04 2018-11-28 Biogen MA Inc. Bruton's tyrosine kinase inhibitors
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
US8679511B2 (en) * 2009-10-01 2014-03-25 Duquesne University of the Holy Spririt In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts
KR101947307B1 (ko) 2009-10-06 2019-02-12 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｐｄｋ１ 저해제로서 유용한 헤테로시클릭 화합물
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
WO2011056604A2 (en) 2009-10-26 2011-05-12 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
CN102711765A (zh) 2009-11-16 2012-10-03 加利福尼亚大学董事会 激酶抑制剂
KR101849680B1 (ko) 2009-12-10 2018-04-17 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 아밀로이드 결합제
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
DE102010009475B4 (de) 2010-02-26 2011-11-24 F. Holzer Gmbh Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
EP2555748A2 (en) 2010-04-07 2013-02-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
EP2555750A2 (en) 2010-04-07 2013-02-13 Allergan, Inc. Combinations of preservative compositions for ophthalmic formulations
JP5713791B2 (ja) * 2010-05-12 2015-05-07 テイカ製薬株式会社 眼科用剤
KR20130100273A (ko) 2010-08-27 2013-09-10 와카모토 세이야꾸 가부시끼가이샤 점안용 수성 조성물
US8530449B2 (en) 2010-09-09 2013-09-10 Assad S. Sawaya Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye
JP5890951B2 (ja) 2010-09-13 2016-03-22 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
US20130324606A1 (en) 2011-02-14 2013-12-05 Allergan, Inc. Ester Derivatives of Bimatoprost Compositions and Methods
KR102052670B1 (ko) 2011-05-17 2019-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키나아제 저해제
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
JP5974084B2 (ja) 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
JP2014521594A (ja) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 長持続期間デュアルホルモンコンジュゲート
AU2012279154A1 (en) 2011-07-01 2014-02-20 The Regents Of The University Of California Herpes virus vaccine and methods of use
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
WO2013063492A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
CN104379563B (zh) 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9353087B2 (en) 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
WO2013188452A1 (en) 2012-06-11 2013-12-19 The Regents Of The University Of California Compounds and methods of treating cancer
ES2711425T3 (es) 2012-08-27 2019-05-03 Allergan Inc Espesamiento de la córnea central reducido mediante el uso de profármacos de éster hidrófilos de beta-clorociclopentanos
US9090595B2 (en) 2012-08-27 2015-07-28 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
SMT201900344T1 (it) 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
CA2900335C (en) 2012-10-22 2021-10-26 City Of Hope Synthetic analogs of epipolythiodioxopiperazines and uses thereof
US9364462B2 (en) 2012-10-30 2016-06-14 The Regents Of The University Of California Alpha-1-adrenergic receptor agonist therapy
EP2953950B1 (en) 2013-02-11 2021-01-13 The Regents of The University of California Compositions and methods for treating neurodegenerative diseases
EP2968296B1 (en) 2013-03-12 2020-09-02 The Regents of the University of California Gamma-secretase modulators
WO2014143591A1 (en) 2013-03-12 2014-09-18 Allergan, Inc. Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
US9321745B2 (en) 2013-03-12 2016-04-26 Allergan, Inc. Inhibition of neovascularization by inhibition of prostanoid IP receptors
HK1220197A1 (zh) 2013-03-14 2017-04-28 City Of Hope 5-溴-靛玉紅
CN115177626A (zh) 2013-03-14 2022-10-14 加利福尼亚大学董事会 硫代糖粘液溶解剂及其应用和组合物
EP2968270A4 (en) 2013-03-14 2016-08-17 Univ California MODULATION OF K2P CHANNELS
EA032227B1 (ru) 2013-03-15 2019-04-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Сложные диэфиры ациклических нуклеозидфосфонатов
DK2968297T3 (da) 2013-03-15 2019-01-07 Verseon Inc Multisubstituerede aromatiske forbindelser som serinproteasehæmmere
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
CA2904794C (en) 2013-03-15 2021-11-23 Peter Walter Modulators of the eif2alpha pathway
WO2014146111A2 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Analgesic compounds and methods of use
CN105338985A (zh) 2013-03-15 2016-02-17 阿勒根公司 用于增加瘦素生成的比马前列素
MX373646B (es) 2013-03-15 2020-04-02 Verseon Corp Halogeno-pirazoles como inhibidores de trombina.
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP2999472B1 (en) 2013-05-22 2020-07-22 The Regents of The University of California Aurora kinase inhibitors
US9795691B2 (en) 2013-06-24 2017-10-24 City Of Hope Chemically-linked nanoparticles
CA2917527C (en) 2013-07-15 2022-06-14 Board Of Regents, The University Of Texas System Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
PT3035926T (pt) 2013-08-19 2020-09-01 Univ California Compostos e métodos para tratar um distúrbio epiléptico
JP2016530273A (ja) 2013-08-20 2016-09-29 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 癌を治療するためのｈｄａｃ８阻害剤
WO2015031799A1 (en) 2013-08-30 2015-03-05 The Regents Of The University Of California, A California Corporation Scintillator nanocrystal-containing compositions and methods for their use
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN109096274B (zh) 2013-12-11 2022-07-01 比奥根Ma公司 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
BR112016014758A8 (pt) 2013-12-23 2020-06-02 Memorial Sloan Kettering Cancer Center composto e método para a marcação radioativa e composição farmacêutica compreendendo o referido composto
JP2017502089A (ja) 2014-01-10 2017-01-19 マニスティー パートナーズ エルエルシーＭａｎｉｓｔｅｅ Ｐａｒｔｎｅｒｓ Ｌｌｃ 偏頭痛の処置
WO2015116856A2 (en) 2014-01-29 2015-08-06 City Of Hope Farnesoid x receptor antagonists
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
JP6889433B2 (ja) 2014-02-14 2021-06-18 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 薬剤の選択的送達のためのプロドラッグとしての環状ペルオキシド
WO2015175075A1 (en) 2014-02-20 2015-11-19 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
BR112016018948B1 (pt) 2014-02-21 2023-01-17 Principia Biopharma Inc Uso de composto ou sal farmaceuticamente aceitável, ácido sulfônico ou sal de ácido carboxílico de composto, forma amorfa de sal farmaceuticamente aceitável de composto, composição farmacêutica e respectivo uso
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
EP3128842B1 (en) 2014-03-26 2023-07-26 City of Hope Treatment of brca1-defective cancer or resistant cancers
EP3988540A1 (en) 2014-04-07 2022-04-27 The Regents of the University of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments
EP3143013B1 (en) 2014-05-13 2019-12-18 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
US10414814B2 (en) 2014-07-03 2019-09-17 City Of Hope Tumor-selective CTLA-4 antagonists
WO2016018917A2 (en) 2014-07-28 2016-02-04 The Regents Of The University Of Califoria Compositions and methods of making polymerized nucleic acids
WO2016023036A1 (en) 2014-08-08 2016-02-11 The Regents Of The University Of California High density peptide polymers
WO2016040806A1 (en) 2014-09-11 2016-03-17 The Regents Of The University Of California mTORC1 INHIBITORS
JP6708329B2 (ja) 2014-09-15 2020-06-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヌクレオチド類似体
RU2017112739A (ru) 2014-09-17 2018-10-17 Версеон Корпорейшн Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
ES2826443T3 (es) 2014-09-25 2021-05-18 Araxes Pharma Llc Inhibidores de proteínas mutantes KRAS G12C
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
CN111978310A (zh) 2014-10-02 2020-11-24 阿勒根公司 γ-内酰胺的酯前药及其用途
WO2016061145A1 (en) 2014-10-13 2016-04-21 Symic Biomedical, Inc. Synthetic proteoglycans for preventing tissue adhesion
WO2016061147A1 (en) 2014-10-13 2016-04-21 John Eric Paderi Luminal vessel coating for arteriovenous fistula
WO2016065083A1 (en) 2014-10-21 2016-04-28 Symic Biomedical, Inc. Peptidoglycans comprising collagen-binding peptides for treating gastroesophageal injury
EP3233103B1 (en) 2014-12-18 2020-10-14 Principia Biopharma Inc. Treatment of pemphigus
WO2016115275A1 (en) 2015-01-13 2016-07-21 City Of Hope Ctla4-binding protein peptide-linker masks
US11730789B2 (en) 2015-01-16 2023-08-22 City Of Hope Cell penetrating antibodies
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
JP6884703B2 (ja) 2015-02-25 2021-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 障害を治療するための５ｈｔ作動薬
CN107531687A (zh) 2015-02-27 2018-01-02 加利福尼亚大学董事会 能够实现软骨复壮的小分子
CN107530304A (zh) 2015-02-27 2018-01-02 科泰纳制药公司 Olig2活性的抑制
WO2016138532A1 (en) 2015-02-27 2016-09-01 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2016141056A1 (en) 2015-03-02 2016-09-09 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
WO2016161018A1 (en) 2015-03-30 2016-10-06 City Of Hope Mechanically interlocking complexes
KR20180005178A (ko) 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 치환된 퀴나졸린 화합물 및 이의 사용방법
MX2017013275A (es) 2015-04-15 2018-01-26 Araxes Pharma Llc Inhibidores triciclicos fusionados de kras y metodos de uso de los mismos.
US10752612B2 (en) 2015-04-17 2020-08-25 Ludwig Institute For Cancer Research Ltd PLK4 inhibitors
EP3286214B1 (en) 2015-04-24 2023-12-06 The Regents of the University of California Modulators of ror1-ror2 binding
AU2016265845B2 (en) 2015-05-15 2020-10-08 City Of Hope Chimeric antigen receptor compositions
US10787664B2 (en) 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
US10765696B2 (en) 2015-06-10 2020-09-08 City Of Hope Compositions of and methods of treatment with zwitterionic polysaccharide
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
CN114224907A (zh) 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
CN108135958B (zh) 2015-08-06 2022-03-04 希望之城 细胞穿透蛋白-抗体缀合物及其使用方法
EP3128007A1 (en) 2015-08-07 2017-02-08 Gene Signal International SA Sterile emulsion comprising a stable phosphorothioate oligonucleotide
US11136301B2 (en) 2015-08-31 2021-10-05 The Regents of the University of California, A California Corporation et al. Broad spectrum antiviral compounds and uses thereof
WO2017040982A1 (en) 2015-09-02 2017-03-09 The Regents Of The University Of California Her3 ligands and uses thereof
JP6933644B2 (ja) 2015-09-04 2021-09-08 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ アンドロゲン受容体拮抗薬
AU2016325601C1 (en) 2015-09-25 2022-03-31 Ludwig Institute For Cancer Research Ltd. 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US20170112941A1 (en) 2015-10-13 2017-04-27 Symic Ip, Llc Ve-cadherin binding bioconjugate
EP3364984B1 (en) 2015-10-15 2021-11-17 City of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC PROCESS FOR SCREENING INHIBITORS OF RAS
CN119241632A (zh) 2015-10-23 2025-01-03 Erx制药股份有限公司 雷公藤红素的类似物
EP3364971B1 (en) 2015-10-23 2020-06-17 Sunesis Pharmaceuticals, Inc. Heterocyclic pdk1 inhibitors for use to treat cancer
US11058700B2 (en) 2015-10-28 2021-07-13 City Of Hope Macrocyclic lactones and uses thereof as modulators of purinergic receptors
EP3377481A1 (en) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
EP3386549A4 (en) 2015-12-10 2019-08-07 City of Hope Cell penetrating cyanine-coupled antibodies
AU2016377785B2 (en) 2015-12-24 2021-07-01 The Regents Of The University Of California CFTR regulators and methods of use thereof
BR112018012949B1 (pt) 2015-12-24 2023-11-14 The Regents Of The University Of California Reguladores cftr e métodos de uso dos mesmos
US10675273B2 (en) 2016-01-05 2020-06-09 The Regents Of The University Of California Benzothiazole amphiphiles
US10519442B2 (en) 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
EP3430017B1 (en) 2016-03-17 2023-01-25 The Regents of The University of California Compositions and methods for treating parasitic diseases
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
GR1009006B (el) 2016-04-01 2017-04-04 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χρηση περιεχον βιματοπροστη και τιμολολη
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
ES2886935T3 (es) 2016-04-25 2021-12-21 Forma Therapeutics Inc Inhibidores de FASN para su uso en el tratamiento de esteatohepatitis no alcohólica
AU2017257151A1 (en) 2016-04-29 2018-11-15 Board Of Regents, The University Of Texas System Sigma receptor binders
TWI763668B (zh) 2016-05-05 2022-05-11 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
MA44968A (fr) 2016-05-12 2019-03-20 Anacor Pharmaceuticals Inc Esters d'oxaborole et leurs utilisations
EP3463342B1 (en) 2016-05-26 2023-09-06 The Regents of The University of California Estrogen receptor modulator combinations
CN115054586B (zh) 2016-06-29 2024-08-02 普林斯匹亚生物制药公司 改性的释放制剂
US11045493B2 (en) 2016-07-11 2021-06-29 The Regents Of The University Of California Synthetic melanin nanoparticles and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3487852A1 (en) 2016-07-21 2019-05-29 Biogen MA Inc. Succinate forms and compositions of bruton's tyrosine kinase inhibitors
CA3032133A1 (en) 2016-07-29 2018-02-01 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
US11254667B2 (en) 2016-08-17 2022-02-22 Children's Hospital Medical Center Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
WO2018039612A1 (en) 2016-08-26 2018-03-01 The Regents Of The University Of California Compositions and methods for promoting hair growth with mpc1 inhibitors
JP7063885B2 (ja) 2016-09-13 2022-05-09 ザ ジャクソン ラボラトリー 標的にされた増大するｄｎａ脱メチル化
EP3512520B1 (en) 2016-09-15 2023-06-21 City of Hope Dithio derivatives of epidithiodiketopiperazine (etp)
US10849955B2 (en) 2016-09-28 2020-12-01 City Of Hope Methods of treating pancreatic cancer using GPCR antagonists
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
RU2019121922A (ru) 2016-12-15 2021-01-18 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Композиции и способы лечения рака
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
LT3576753T (lt) 2017-02-03 2024-07-25 Laboratoires Kôl Sterili emulsija, apimanti stabilų fosforotioato oligonukleotidą
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
EP3630746A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Compounds and methods of use thereof for treatment of cancer
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
CA3067695A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
US11554178B2 (en) 2017-06-30 2023-01-17 City Of Hope Compositions and methods of modulating macrophage activity
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
US11389460B2 (en) 2017-09-15 2022-07-19 City Of Hope Methods and compositions for treating endometrial cancer
WO2019067015A1 (en) 2017-09-29 2019-04-04 City Of Hope RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
CN111386283A (zh) 2017-09-29 2020-07-07 基因泰克公司 肽抗菌复合物及其使用方法
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
CA3078942A1 (en) 2017-10-10 2019-04-18 Syros Pharmaceuticals, Inc. Pyrrolotriazine compounds and methods of inhibiting tam kinases
US11618780B2 (en) 2017-10-20 2023-04-04 City Of Hope Composition and method for activating latent human immunodeficiency virus (HIV)
AU2018358157B2 (en) 2017-11-02 2023-03-09 Abbvie Inc. Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
US11939320B2 (en) 2017-11-02 2024-03-26 Abbvie Inc. Modulators of the integrated stress pathway
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
CN112154142B (zh) 2017-11-02 2023-11-21 卡里科生命科学有限责任公司 整合应激通路的调节剂
WO2019090090A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
BR112020008817B8 (pt) 2017-11-02 2023-10-03 Abbvie Inc Compostos moduladores da via de estresse integrada
CN112218851A (zh) 2017-11-02 2021-01-12 卡里科生命科学有限责任公司 整合应激通路的调节剂
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제
WO2019113542A1 (en) 2017-12-07 2019-06-13 Amplyx Pharmaceuticals, Inc. Heterocycle substituted pyridine derivative antifungal agents
US11939575B2 (en) 2017-12-19 2024-03-26 City Of Hope Modified tracrRNAs gRNAs, and uses thereof
CA3088526A1 (en) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2019143730A1 (en) 2018-01-16 2019-07-25 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
MX2020007812A (es) 2018-01-26 2020-11-24 Rapt Therapeutics Inc Moduladores del receptor de quimiocina y usos de los mismos.
US10730874B2 (en) 2018-03-13 2020-08-04 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein and uses thereof
AU2019260793B2 (en) 2018-04-27 2023-05-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
CN118894869A (zh) 2018-05-01 2024-11-05 锐新医药公司 作为mTOR抑制剂的C40-、C28-及C-32连接的雷帕霉素类似物
EP3788050B1 (en) 2018-05-01 2024-08-28 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
WO2019213611A1 (en) 2018-05-04 2019-11-07 Cirius Therapeutics, Inc. Thiazolidinedione analogs for the treatment of nafld and metabolic diseases
US11046699B2 (en) 2018-06-05 2021-06-29 Rapt Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
BR112020026086A2 (pt) 2018-06-21 2021-03-23 Calico Life Sciences Llc inibidores da proteína tirosina fosfatase e métodos de uso destes
EP3810115B1 (en) 2018-06-25 2024-07-17 Basilea Pharmaceutica International AG, Allschwil Pyridine derivatives substituted by heterocyclic ring and amino group
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20210221864A1 (en) 2018-08-24 2021-07-22 City Of Hope Masked cytokine conjugates
CN112955187A (zh) 2018-09-10 2021-06-11 加利福尼亚大学董事会 二硫醇糖粘液溶解剂和其用途
TWI832295B (zh) 2018-10-11 2024-02-11 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑
BR112021008128A2 (pt) 2018-11-01 2021-08-03 Lynk Pharmaceuticals Co. Ltd. inibidores de janus quinase 1 tricíclicos, e composições e métodos dos mesmos
CA3121155C (en) * 2018-11-26 2023-09-05 Aiviva Biopharma, Inc. Pharmaceutical biodissolvable gels for drug delivery
MX2021010544A (es) 2019-03-14 2021-10-01 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
SG11202111918PA (en) 2019-04-30 2021-11-29 Calico Life Sciences Llc Substituted cycloalkyls as modulators of the integrated stress pathway
FR3095592B1 (fr) * 2019-05-02 2021-05-21 Unither Pharmaceuticals Composition à base de gomme gellane et de phényléphrine, procédé de fabrication et utilisation comme produit ophtalmique
EP3968979A4 (en) 2019-05-15 2023-03-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
US20220267753A1 (en) 2019-06-14 2022-08-25 Children's Hospital Medical Center Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n
JOP20220068A1 (ar) 2019-09-18 2023-01-30 Novartis Ag بروتينات اندماج nkg2d واستخداماتها
CN114667289A (zh) 2019-09-18 2022-06-24 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
FI4031547T3 (fi) 2019-09-18 2024-09-16 Takeda Pharmaceuticals Co Plasman kallikreiinin estäjiä ja niiden käyttötapoja
IL291994A (en) 2019-10-14 2022-06-01 Principia Biopharma Inc Methods for treating immune thrombocytopenia by administering (r)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
AU2020383625A1 (en) 2019-11-13 2022-05-05 Rapt Therapeutics, Inc. Crystalline forms of C-C chemokine receptor type 4 antagonist and uses thereof
CA3162069A1 (en) 2019-12-18 2021-06-24 Elliot P. Farney Protein tyrosine phosphatase inhibitors and methods of use thereof
WO2021198911A1 (en) 2020-03-31 2021-10-07 Sentiss Pharma Private Limited A sterilization process of timolol gel forming solution through aseptic filtration
GR1010024B (el) 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
EP4153564A4 (en) 2020-05-19 2024-06-19 Cybin IRL Limited DEUTERATED TRYPTAMINE DERIVATIVES AND METHODS OF USE
AU2021327136A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Therapeutic phenethylamine compositions and methods of use
US20240398807A1 (en) 2020-10-02 2024-12-05 Mitokinin, Inc. Compositions and methods of treating kidney disease and fibrosis
WO2022094409A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof
CA3198795A1 (en) 2020-11-18 2022-05-27 Jeffrey Becker Complexing agent salt formulations of pharmaceutical compounds
WO2022133237A2 (en) 2020-12-18 2022-06-23 Cornell University Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
CN117355523A (zh) 2021-03-17 2024-01-05 武田药品工业株式会社 血浆激肽释放酶的多环抑制剂
JP2024510502A (ja) 2021-03-17 2024-03-07 武田薬品工業株式会社 血漿カリクレインのイミダゾピリジニル阻害剤
AU2022240596A1 (en) 2021-03-17 2023-10-19 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein
CN117396474A (zh) 2021-03-17 2024-01-12 武田药品工业株式会社 血浆激肽释放酶抑制剂
WO2022197763A1 (en) 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Inhibitors of plasma kallikrein
AU2023222126A1 (en) 2022-02-15 2024-08-08 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
KR20240153566A (ko) 2022-02-15 2024-10-23 사이빈 아이알엘 리미티드 치료적 펜에틸아민 조성물, 및 사용 방법
CN119585256A (zh) 2022-04-06 2025-03-07 拉普特医疗公司 趋化因子受体调节剂及其用途
EP4531859A1 (en) 2022-05-25 2025-04-09 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
US20250034115A1 (en) 2023-07-12 2025-01-30 Rapt Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
WO2025015189A1 (en) 2023-07-13 2025-01-16 Comanche Biopharma Corp. Formulations of nucleic acid compounds and uses thereof
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025068803A1 (en) 2023-09-26 2025-04-03 Astrazeneca Ab Therapeutic combinations comprising anti-steap2 chimeric antigen receptor t cells
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2441729A (en) * 1943-12-08 1948-05-18 Kelco Co Algin gel-forming compositions
US2935447A (en) * 1957-02-19 1960-05-03 Kelco Co Appetite depressant containing alginate
FR1312244A (fr) * 1962-01-09 1962-12-14 Bernburg Serum Werk Veb Procédé de fabrication de supports de pommade exempts de corps gras
BE731578A (da) * 1969-04-16 1969-10-01
US4013792A (en) * 1974-04-11 1977-03-22 Warner-Lambert Company Process for the production of base for topical steroids
AU7776275A (en) * 1974-04-11 1976-08-05 Warner Lambert Co Production of base for topical steroids
NL188266C (nl) * 1975-07-29 1992-05-18 Merck & Co Inc Werkwijze ter bereiding van een oogheelkundig inplantaat.
US4039662A (en) * 1975-12-04 1977-08-02 Alcon Laboratories, Inc. Ophthalmic solution
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
CA1072413A (en) * 1976-07-13 1980-02-26 West Laboratories Poloxamer gel systems with gelling temperatures higher than room temperature
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
KR830002802B1 (ko) * 1978-12-04 1983-12-16 제임스 에프 · 너우톤 박테리아 발효에 의한 다당류 s-60의 제조방법
US4326053A (en) * 1978-12-04 1982-04-20 Merck & Co., Inc. Polysaccharide S-60 and bacterial fermentation process for its preparation
US4409205A (en) * 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4407792A (en) * 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4503084A (en) * 1983-05-31 1985-03-05 Merck & Co., Inc. Non-heated gellan gum gels
US4563366A (en) * 1983-05-31 1986-01-07 Merck & Co., Inc. Non-heated gellan gum gels
GB8318403D0 (en) * 1983-07-07 1983-08-10 Sutherland I W Gel-forming polysaccharides
DE3335593A1 (de) * 1983-09-30 1985-04-11 Diamalt AG, 8000 München Gelier- und verdickungsmittel auf der basis von cassia-galactomannanen
US4717713A (en) * 1983-10-31 1988-01-05 Research Corporation Controlled release liquid pharmaceutical
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
US4517216A (en) * 1984-03-05 1985-05-14 Merck & Co., Inc. Gellan gum/gelatin blends
GB8431699D0 (en) * 1984-12-14 1985-01-30 Mars G B Ltd Gel system

Also Published As

Publication number Publication date
IL80156A0 (en) 1986-12-31
NZ217662A (en) 1990-02-26
FI863990L (fi) 1987-04-04
PT83471B (pt) 1988-11-30
LU88694I2 (fr) 1996-04-29
ES2002401A6 (es) 1988-08-01
LV5725A4 (lv) 1996-02-20
AU595240B2 (en) 1990-03-29
NO173212C (no) 1993-11-17
KR940000229B1 (ko) 1994-01-12
DE3684121D1 (de) 1992-04-09
FI863990A0 (fi) 1986-10-02
FR2588189A1 (fr) 1987-04-10
NO863916L (no) 1987-04-06
AU6318986A (en) 1987-04-09
PT83471A (en) 1986-11-01
NO1995003I1 (no) 1995-04-10
FR2588189B1 (fr) 1988-12-02
ATE72990T1 (de) 1992-03-15
HK42594A (en) 1994-05-13
ZA867464B (en) 1987-07-29
KR870003773A (ko) 1987-05-04
IE862481L (en) 1987-04-03
EP0227494A1 (en) 1987-07-01
DK469886D0 (da) 1986-10-02
CY1779A (en) 1995-10-20
FI91217B (fi) 1994-02-28
NO173212B (no) 1993-08-09
US4861760A (en) 1989-08-29
EP0227494B1 (en) 1992-03-04
IL80156A (en) 1990-09-17
JPS62181228A (ja) 1987-08-08
CN86106637A (zh) 1987-04-08
CA1280367C (en) 1991-02-19
LV5725B4 (lv) 1996-06-20
CN1046094C (zh) 1999-11-03
NO863916D0 (no) 1986-10-02
IE59464B1 (en) 1994-02-23
GR862444B (en) 1987-01-27
FI91217C (fi) 1994-06-10
JPH0667853B2 (ja) 1994-08-31
DE227494T1 (de) 1988-03-17
DK170500B1 (da) 1995-10-02
NL950012I1 (nl) 1996-10-01

Similar Documents

Publication Publication Date Title
DK469886D0 (da) Farmaceutisk praeparat af en type, som undergaar vaeske-gel-fase overgang
FI875533L (fi) Insulinpreparat foer non-parenteral dosering.
IT1205978B (it) Derivati di dicloroanilina,composizioni farmaceutiche che li contengono e procedimento per produrli
AR224243A1 (es) Procedimiento para aumentar la viscosidad de preparados cosmeticos,farmaceuticos y tecnicos
DK0495421T3 (da) Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
BR8206061A (pt) Composicao de gel,pasta ou liquida aquosa
IT8548373A0 (it) Derivati amminopropossi,loro preparazione e loro impiego come medicamenti
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
FI883761A7 (fi) Ionisten tensidien vesipitoisia koostumuksia, joilla on kohonnut viskositeetti
ES428890A1 (es) Preparacion de multivitaminas acuosa estable.
DK498384D0 (da) N-cycliske benzensulfonamider, fremgangsmaade til deres fremstilling og deres anvendelse som aktiv komponent i farmaceutiske kompositioner
BR8700497A (pt) Composicao para preparacao instantanea de formulacoes para aplicacoes topicas
DK159094C (da) Anvendelse af vandige natrium- eller kaliummethioninatoploesninger til supplering af blandingsfoder med methionin
ES2056149T3 (es) Ambliommina, una nueva sustancia activa para la terapia anticoagulante.
ATE82126T1 (de) Zubereitung zum stoppen von angiogenese und einem kapillar-, zellen- oder membranleck.
IT1114869B (it) Derivati attivi di metilammina,composizioni terapeutiche che li contengono e procedimenti per preparare i detti derivati e le dette composizioni
IT1203976B (it) Derivati dell'ergolene, composizioni farmaceutiche che li contengono e procedimento per la preparazione dei medesimi
IT1181736B (it) Derivati di imidazopiridazina,composizione farmaceutica che li contiene e procedimento per prepararli
ES2058316T3 (es) Procedimiento para la obtencion de un medicamento antitusigeno.
FI874823A7 (fi) Farmaseuttinen ainekokoomus käytettäväksiverenpainetta ja verentungosta aiheuttavan sydämen toiminnan vajavuutt
IT7925098A0 (it) Per prepararli e composizione derivati immidazolici, procedimento farmaceutica che li contiene.
KR870000403A (ko) 세멘트 급결 방수제의 제조방법
IT8522901A0 (it) Derivati del diidroubidecarenone, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT8421319A0 (it) Derivati tiolici dell'eritromicina ad attivita' terapeutica, relativo procedimento di preparazione e composizioni farmaceutiche che li contengono.
SU1103398A1 (ru) Антисептический состав "аполам"

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1996 00009, 960328

CTFF Application for supplementary protection certificate (spc) filed

Spc suppl protection certif: CA 1996 00009

Filing date: 19960328

Expiry date: 20080910

PUP Patent expired